| |
| |
|
| Insider
Information: |
Sharp Shalini |
| Relationship: |
|
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
214,123 |
|
|
Indirect Shares
|
104,270 |
|
|
| Direct
Value |
$4,727,964 |
|
|
|
Indirect Value
|
$46,244 |
|
|
| Total
Shares |
318,393 |
|
|
| Total
Value |
$4,774,208 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
6
|
|
Stock
price went up :
|
0
|
5
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
5.0
|
| Percentage
Gain/Loss : |
0.0%
|
 537.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Antigenics Inc |
AGEN |
Director |
2013-01-30 |
81,311 |
2015-09-28 |
104,270 |
Premium* |
|
|
Ultragenyx Pharmaceutical Inc |
RARE |
EVP, Finance |
2020-10-14 |
97,812 |
|
0 |
Premium* |
|
|
Nuvation Bio Ord Shs Class A |
NUVB |
Director |
2021-02-10 |
35,000 |
2021-02-10 |
0 |
Premium* |
|
|
Mirati Therapeutics, Inc. |
MRTX |
|
2024-01-23 |
0 |
2021-03-26 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| MRTX |
Mirati Therapeutics, Inc. |
|
• • – |
2024-01-23 |
4 |
D |
$0.00 |
$0 |
D/D |
(16,222) |
0 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
Director |
– • – |
2023-12-29 |
4 |
A |
$58.75 |
$399,970 |
D/D |
6,808 |
16,222 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
|
– • – |
2023-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
4,444 |
9,414 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
|
– • – |
2022-01-14 |
4 |
A |
$0.00 |
$0 |
D/D |
2,546 |
4,970 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
|
– • – |
2021-03-26 |
4 |
A |
$0.00 |
$0 |
D/D |
2,424 |
2,424 |
0 |
- |
|
| NUVB |
Nuvation Bio Ord Shs Clas... |
Director |
– • – |
2021-02-10 |
4 |
A |
$10.00 |
$100,000 |
D/D |
10,000 |
35,000 |
0 |
- |
|
| NUVB |
Nuvation Bio Ord Shs Clas... |
Director |
– • – |
2021-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,000 |
25,000 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
EVP, Finance |
• – – |
2020-10-14 |
4 |
S |
$87.99 |
$32,996 |
D/D |
(375) |
97,812 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2020-08-17 |
4 |
S |
$88.24 |
$1,271,073 |
D/D |
(14,378) |
98,187 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2020-08-17 |
4 |
OE |
$48.43 |
$698,524 |
D/D |
11,357 |
101,856 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2020-06-04 |
4 |
S |
$74.01 |
$189,762 |
D/D |
(2,564) |
101,208 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2020-06-04 |
4 |
OE |
$48.43 |
$124,175 |
D/D |
2,564 |
103,772 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2020-06-03 |
4 |
S |
$74.23 |
$759,670 |
D/D |
(10,234) |
101,208 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2020-06-03 |
4 |
OE |
$48.43 |
$495,633 |
D/D |
10,234 |
111,442 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2020-06-01 |
4 |
D |
$69.38 |
$24,144 |
D/D |
(348) |
101,208 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2020-05-19 |
4 |
S |
$73.32 |
$522,625 |
D/D |
(7,128) |
101,556 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2020-05-19 |
4 |
OE |
$48.43 |
$431,710 |
D/D |
7,128 |
104,851 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2020-05-18 |
4 |
S |
$73.29 |
$1,612,260 |
D/D |
(21,985) |
100,944 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2020-05-18 |
4 |
OE |
$70.57 |
$1,382,678 |
D/D |
19,593 |
122,929 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2020-05-06 |
4 |
D |
$66.26 |
$16,432 |
D/D |
(248) |
103,336 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2020-04-19 |
4 |
D |
$58.57 |
$14,525 |
D/D |
(248) |
103,584 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2020-03-01 |
4 |
D |
$56.08 |
$130,386 |
D/D |
(2,325) |
103,832 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2020-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,634 |
106,157 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2019-10-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,434 |
100,523 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2019-09-16 |
4 |
OE |
$0.81 |
$176,317 |
D/D |
31,843 |
99,089 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
